Kyrgyzstan
Tuberculosis profile
| High MDR-TB burden |
Population  2013 5.5 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.62 (0.62–0.63) 11 (11–11)
Mortality (HIV+TB only) 0.045 (0.031–0.062) 0.81 (0.55–1.1)
Prevalence  (includes HIV+TB) 11 (4.9–18) 190 (88–329)
Incidence  (includes HIV+TB) 7.8 (6.9–8.7) 141 (124–157)
Incidence (HIV+TB only) 0.24 (0.19–0.26) 4.3 (3.4–4.7)
Case detection, all forms (%) 91 (81–100)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 26 (23–31) 55 (52–58)
MDR-TB cases among notified pulmonary
TB cases
1 100 (950–1 300) 660 (620–700)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 667   415
Pulmonary, clinically diagnosed 2 518   649
Extrapulmonary 1 674   152
       
Total new and relapse 7 075    
Previously treated, excluding relapses 134    
Total cases notified 7 209    
Among 5 859 new cases:
594 (10%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 157 (129%) 993 (74%) 3 150
Laboratory-confirmed RR-/MDR-TB cases     1 191
Patients started on MDR-TB treatment     1 064
TB/HIV 2013 Number (%)
TB patients with known HIV status    
HIV-positive TB patients 203  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 92 (45)
HIV-positive TB patients on antiretroviral therapy (ART) 110 (54)
HIV-positive people screened for TB 1 950  
HIV-positive people provided with IPT 57  
Treatment success rate (%)
New and relapse cases registered in 2012  
Previously treated cases, excluding relapse, registered in 2012  
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 57
XDR-TB cases started on second-line treatment in 2011 21
Laboratories 2013  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 7.2
Drug susceptibility testing (per 5 million population) 1.8
Sites performing Xpert MTB/RIF 8
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 34
% Funded domestically 41%
% Funded internationally 23%
% Unfunded 37%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-04 Data: www.who.int/tb/data